ReviewIndian journal of surgical oncology2025
Role of Stereotactic Ablative Radiotherapy in Primary Renal Cell Carcinoma: A Review of Clinical Trials.
Review in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 90% of kidney cancers are primary renal cell carcinomas (RCCs). Globally, the incidence of RCC has increased by roughly 2% annually during the previous 20 years. Sixty-five percent of patients currently have localized disease, with a 93% 5-year relative survival rate due to its heterogeneous nature. The reason is the incidental detection of small, localized kidney cancers using imaging. While radical or partial nephrectomy is the mainstay of therapy for patients with curative intent, it is associated with a 1.4% perioperative mortality rate. In light of this, radiation is being incorporated into its multidisciplinary management. Prior phase 1 clinical trials with stereotactic ablative radiotherapy (SABR) for primary RCC were characterized by short follow-up periods, incomplete pathologic data, and most patients who were not surgical candidates. Here, our attention has been closely analyzing the phase 2 SABR trials to address advanced clinical approaches and areas of ongoing research for integrating SABR into primary RCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.